Anticancer and cytotoxic properties of the latex of Calotropis procera in a transgenic mouse model of hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 12, Issue 16, 2006, Pages 2517-2522

  Choedon, Tenzin ^a   Mathan, Ganeshan ^a   Arya, Soneera ^b   Kumar, Vijay L ^b   Kumar, Vijay ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anticancer agent; Calotropis procera; Citotoxicity; Differential killing; Hepatocellular carcinoma; Transgenic mice

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CALOTROPIS PROCERA EXTRACT; CASPASE 3; DNA FRAGMENT; LATEX; METHANOL; PETROLEUM ETHER; PROTEIN BCL 2; SILICA GEL; SOLVENT; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AQUEOUS SOLUTION; ARTICLE; CALOTROPIS PROCERA; CANCER CELL CULTURE; CANCER PREVENTION; CELL DEATH; CELL SEPARATION; CELL STRAIN COS1; CELL TRANSFORMATION; CONTROLLED STUDY; DESICCATION; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG MECHANISM; DRUG TARGETING; HISTOPATHOLOGY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MEDICINAL PLANT; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; SUSPENSION; TRANSGENIC MOUSE; TROPICS;

EID: 33646446931     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i16.2517     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
2. Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001; 411: 390-395
3. Downey RJ. Surgical management of lung cancer. J Thorac Imaging 1999; 14: 266-269
4. Kinne DW. The surgical management of primary breast cancer. CA Cancer J Clin 1991; 41: 71-84
5. Chay CH, Cooper CC, Hellerstedt BA, Pienta KJ. Antimetastatic drugs in prostate cancer. Clin Prostate Cancer 2002; 1: 14-19
6. Hudis CA. Current status and future directions in breast cancer therapy. Clin Breast Cancer 2003; 4 Suppl 2: S70-S75
7. Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol 2003; 9: 1885-1891
8. Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N, Kearney N, Patiraki E. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 2005; 16: 655-663
9. Yates JS, Mustian KM, Morrow GR, Gillies LJ, Padmanaban D, Atkins JN, Issell B, Kirshner JJ, Colman LK. Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 2005; 13: 806-811
10. Kumar VL, Arya S. Medicinal uses and pharmacological properties of Calotropis procera. In: Govil JN, ed. Recent Progress in Medicinal Plants. Texas: Studium Press 2006; 11: 373-388
11. Smit HF, Woerdenbag HJ, Singh RH, Meulenbeld GJ, Labadie RP, Zwaving JH. Ayurvedic herbal drugs with possible cytostatic activity. J Ethnopharmacol 1995; 47: 75-84
12. Van Quaquebeke E, Simon G, Andre A, Dewelle J, Yazidi ME, Bruyneel F, Tuti J, Nacoulma O, Guissou P, Decaestecker C, Braekman JC, Kiss R, Darro F. Identification of a novel cardenolicle (2″-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses. J Med Chem 2005; 48: 849-856
13. Basu A, Chaudhuri AK. Preliminary studies on the antiinflammatory and analgesic activities of Calotropis procera root extract. J Ethnopharmacol 1991; 31: 319-324
14. Mascolo N, Sharma R, Jain SC, Capasso F. Ethnopharmacology of Calotropis procera flowers. J Ethnopharmacol 1988; 22: 211-221
15. Arya S, Kumar VL. Antiinflammatory efficacy of extracts of latex of Calotropis procera against different mediators of inflammation. Mediators Inflamm 2005; 14: 228-232
16. Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005; 13: 559-583
17. Kumar VL, Kumar V. Extraction of latex of Calotropis procera and a process for the preparation thereof, Indian Patent Application # 737/DEL/ 2004 and PCT/IN2005/000106
18. Lakhtakia R, Kumar V, Reddi H, Mathur M, Dattagupta S, Panda SK. Hepatocellular carcinoma in a hepatitis B 'x' transgenic mouse model: A sequential pathological evaluation. J Gastroenterol Hepatol 2003; 18: 80-91
19. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982; 42: 3858-3863
20. van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG, Langenhuijsen MM. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods 1994; 174: 311-320
21. Sambrook J, Russell DW. Molecular Cloning: A laboratory Manual 3rded. New York: Cold Spring Harbor Laboratory, 2001
22. Ohshima H, Tazawa H, Sylla BS, Sawa T. Prevention of human cancer by modulation of chronic inflammatory processes. Mutat Res 2005; 591: 110-122
23. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039
24. Tang TC, Poon RT, Lau CP, Xie D, Fan ST. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol 2005; 11: 1896-1902
25. Cheng AS, Chan HL, To KF, Leung WK, Chan KK, Liew CT, Sung JJ. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int J Oncol 2004; 24: 853-860
26. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G, Goldhirsch A. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13: 73-80
27. Deplanque G, Madhusudan S, Jones PH, Wellmann S, Christodoulos K, Talbot DC, Ganesan TS, Blann A, Harris AL. Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. Br J Cancer 2004; 91: 1645-1650
28. Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, Grilli C, Virzi V, Gasparro S, Rocci L, Tonini G. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005; 25: 144-151
29. Begin ME, Ells G, Das UN, Horrobin DF. Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J Natl Cancer Inst 1986; 77: 1053-1062
30. Chow M, Rubin H. Selective killing of preneoplastic and neoplastic cells by methotrexate with leucovorin. Proc Natl Acad Sci USA 1998; 95: 4550-4555
31. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-219
32. Rollet-Labelle E, Grange MJ, Elbim C, Marquetty C, Gougerot-Pocidalo MA, Pasquier C. Hydroxyl radical as a potential intracellular mediator of polymorphonuclear neutrophil apoptosis. Free Radic Biol Med 1998; 24: 563-572